Hi Asa
We mostly gave similar scores to the PRECIS-2 domains in the two studies, and the majority of our arguments were also similar. The largest difference in our scores relate to the primary outcome in the Amanyire study. I also looked at Sanithia’s evaluation of the studies, and she argued similarly to you, so I might be on the wrong track with my justification. By giving just 1 point, I argued that ART initiation was not an outcome that was of significant importance to the patients (because overall, I think that most of the people don’t like to take medications, but they take them because they’re interested in preventing an outcome (such as AIDS, death) that is of primary interest to them). I’m looking forward to discussing this further in class.
We also scored quite differently on the primary analysis domain of the Rosen study. I did not think of it as being a problem that non-eligible patients that were not randomized in the first place were excluded from the analysis, because it seems that this is what happens in most studies, but I’m curious to hear more about this, and I might have missed something there!